European school of oncology task force papers: Gene therapy—a future in cancer management?In situ delivery of suicide genes for cancer treatment
References (18)
- et al.
Gene therapy for cancer
Trends Genet
(1994) Tumour chemosensitivity conferred by inserted herpes thymadine kinase genes: paradigm for a prospective cancer controlled strategy
Cancer Res
(1986)- et al.
Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a new negative selection system
- et al.
In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumours
Science
(1992) - et al.
In situ retroviral-mediated gene transfer for the treatment of brain tumours in rats
Cancer Res
(1993) - et al.
Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumours
J Neurosurg
(1993) - et al.
In vivo transfer of the human interleukin-2 gene is not tumouricidal for experimental brain tumours
J Neurosurg
(1994) - Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH. The effect of tumour vasculature and growth of...
- Ram Z, Walbridge S, Oshiro EM, et al. Intrathecal gene therapy for the treatment of meningeal carcinomatosis. Cancer...
Cited by (36)
Novel selective human mitochondrial kinase inhibitors: Design, synthesis and enzymatic activity
2007, Bioorganic and Medicinal ChemistryThe role of new agents in the treatment of non-small cell lung cancer
2002, European Journal of CancerCitation Excerpt :Although intratumoral injection with Ad-TP53 showed evidence of clinical activity when given in combination with cisplatin [201], it did not provide any additional benefit in patients receiving an effective first-line chemotherapy for advanced NSCLC in another trial [202]. Suicide gene therapy involves the delivery of a specific gene to the tumour cells, encoding for an enzyme that catalyses the conversion of a systemically administered, non-toxic pro-drug into its active form [203–205]. The most widely used gene in this respect is the herpes simplex virus thymidine kinase (HSV TK).
Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy
2002, Molecular TherapyCitation Excerpt :Essential to the anti-tumor effect of HSVtk/GCV suicide gene therapy is the “bystander effect”, in which non-transduced neighboring cells are killed through the transfer of phosphorylated GCV via gap junctions. Release of tumor antigens by the dying cells may also induce systemic anti-tumor immunity [13–16]. However, previous clinical studies [17] demonstrated that HSVtk therapy neither improved time to progression nor overall survival time, and preclinical studies demonstrated only limited tumor protection or tumor regression in low-or non-immunogenic tumor models [18,19].
Novel approaches to the treatment of non-small cell lung cancer
2002, Critical Reviews in Oncology/HematologyAdeno-associated viral-mediated gene transfer to hepatoma: Thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals
2000, Molecular TherapyCitation Excerpt :However, in experiments in which TK-transduced and untransduced cells were mixed, tumor suppression was incomplete. Critical to the success of HSV-TK/GCV treatment is the so-called “bystander effect,” which confers cytotoxicity to neighboring nontransduced cells (6). Previous experiments have demonstrated that the bystander effect of the HSV-TK/GCV system is stronger in immunocompetent mice than in immunodeficient mice and is associated with CD4+ and CD8+ lymphocyte infiltration (3, 7) and cytokine release (8).
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
1999, Pharmacology and Therapeutics